432 related articles for article (PubMed ID: 15767449)
1. The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.
Peng R; Moses SC; Tan J; Kremmer E; Ling PD
J Virol; 2005 Apr; 79(7):4492-505. PubMed ID: 15767449
[TBL] [Abstract][Full Text] [Related]
2. The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).
Gross H; Barth S; Pfuhl T; Willnecker V; Spurk A; Gurtsevitch V; Sauter M; Hu B; Noessner E; Mueller-Lantzsch N; Kremmer E; Grässer FA
Int J Cancer; 2011 Sep; 129(5):1105-15. PubMed ID: 21710493
[TBL] [Abstract][Full Text] [Related]
3. EBNA2 and Its Coactivator EBNA-LP.
Kempkes B; Ling PD
Curr Top Microbiol Immunol; 2015; 391():35-59. PubMed ID: 26428371
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naïve B cells, and facilitates recruitment of transcription factors to the viral genome.
Szymula A; Palermo RD; Bayoumy A; Groves IJ; Ba Abdullah M; Holder B; White RE
PLoS Pathog; 2018 Feb; 14(2):e1006890. PubMed ID: 29462212
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis of the Epstein-Barr virus-coded leader protein EBNA-LP as a co-activator of EBNA2 function.
McCann EM; Kelly GL; Rickinson AB; Bell AI
J Gen Virol; 2001 Dec; 82(Pt 12):3067-3079. PubMed ID: 11714985
[TBL] [Abstract][Full Text] [Related]
6. Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses.
Peng R; Gordadze AV; Fuentes Pananá EM; Wang F; Zong J; Hayward GS; Tan J; Ling PD
J Virol; 2000 Jan; 74(1):379-89. PubMed ID: 10590127
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2.
Lin J; Johannsen E; Robertson E; Kieff E
J Virol; 2002 Jan; 76(1):232-42. PubMed ID: 11739688
[TBL] [Abstract][Full Text] [Related]
8. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
Ling PD; Hsieh JJ; Ruf IK; Rawlins DR; Hayward SD
J Virol; 1994 Sep; 68(9):5375-83. PubMed ID: 8057421
[TBL] [Abstract][Full Text] [Related]
9. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
[TBL] [Abstract][Full Text] [Related]
10. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
[TBL] [Abstract][Full Text] [Related]
11. DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines.
Sauder C; Haiss P; Grässer FA; Zimber-Strobl U; Mueller-Lantzsch N
J Gen Virol; 1994 Nov; 75 ( Pt 11)():3067-79. PubMed ID: 7964616
[TBL] [Abstract][Full Text] [Related]
12. EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding.
Portal D; Zhao B; Calderwood MA; Sommermann T; Johannsen E; Kieff E
Proc Natl Acad Sci U S A; 2011 May; 108(19):7808-13. PubMed ID: 21518914
[TBL] [Abstract][Full Text] [Related]
13. Conserved regions in the Epstein-Barr virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2.
Peng R; Tan J; Ling PD
J Virol; 2000 Nov; 74(21):9953-63. PubMed ID: 11024123
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.
Pegman PM; Smith SM; D'Souza BN; Loughran ST; Maier S; Kempkes B; Cahill PA; Simmons MJ; Gélinas C; Walls D
J Virol; 2006 Aug; 80(16):8133-44. PubMed ID: 16873269
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells.
Allday MJ; Crawford DH; Thomas JA
J Gen Virol; 1993 Mar; 74 ( Pt 3)():361-9. PubMed ID: 8383171
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter.
Jiménez-Ramírez C; Brooks AJ; Forshell LP; Yakimchuk K; Zhao B; Fulgham TZ; Sample CE
J Virol; 2006 Nov; 80(22):11200-8. PubMed ID: 16956945
[TBL] [Abstract][Full Text] [Related]
18. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
Schlager S; Speck SH; Woisetschläger M
J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
[TBL] [Abstract][Full Text] [Related]
19. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.
Radkov SA; Bain M; Farrell PJ; West M; Rowe M; Allday MJ
J Virol; 1997 Nov; 71(11):8552-62. PubMed ID: 9343213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
